BR112019008431A2 - aplicação de (s)-norcetamina e sal da mesma como fármaco - Google Patents

aplicação de (s)-norcetamina e sal da mesma como fármaco

Info

Publication number
BR112019008431A2
BR112019008431A2 BR112019008431A BR112019008431A BR112019008431A2 BR 112019008431 A2 BR112019008431 A2 BR 112019008431A2 BR 112019008431 A BR112019008431 A BR 112019008431A BR 112019008431 A BR112019008431 A BR 112019008431A BR 112019008431 A2 BR112019008431 A2 BR 112019008431A2
Authority
BR
Brazil
Prior art keywords
drug
depression
norcetamine
prevention
treatment
Prior art date
Application number
BR112019008431A
Other languages
English (en)
Inventor
Hashimoto Kenji
Original Assignee
Univ Chiba Nat Univ Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chiba Nat Univ Corp filed Critical Univ Chiba Nat Univ Corp
Publication of BR112019008431A2 publication Critical patent/BR112019008431A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

a presente invenção refere-se a: um fármaco para a prevenção e/ou o tratamento de um sintoma de depressão, o fármaco compreendendo (s)-norcetamina ou um sal farmacologicamente aceitável da mesma; uma composição farmacêutica para a prevenção e/ou o tratamento de um sintoma de depressão, a composição contendo (s)-norcetamina ou um sal farmacologicamente aceitável da mesma em uma quantidade eficaz para aliviar sintomas de depressão, e substancialmente não contendo (r)-norcetamina; um método para a prevenção e/ou o tratamento de sintomas de depressão, o método incluindo a administração do fármaco ou da composição; e uso de (s)-norcetamina na produção de um fármaco para a prevenção e/ou o tratamento de sintomas de depressão ou uma composição para a prevenção e/ou o tratamento de sintomas de depressão.
BR112019008431A 2016-10-27 2017-10-27 aplicação de (s)-norcetamina e sal da mesma como fármaco BR112019008431A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016210749 2016-10-27
PCT/JP2017/038826 WO2018079693A1 (ja) 2016-10-27 2017-10-27 （ｓ）－ノルケタミンおよびその塩の医薬品としての応用

Publications (1)

Publication Number Publication Date
BR112019008431A2 true BR112019008431A2 (pt) 2019-07-09

Family

ID=62023567

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019008431A BR112019008431A2 (pt) 2016-10-27 2017-10-27 aplicação de (s)-norcetamina e sal da mesma como fármaco

Country Status (9)

Country Link
US (1) US20190240184A1 (pt)
EP (1) EP3533444A4 (pt)
JP (3) JPWO2018079693A1 (pt)
CN (1) CN110167541A (pt)
AU (1) AU2017351437B2 (pt)
BR (1) BR112019008431A2 (pt)
CA (1) CA3041275A1 (pt)
IL (1) IL266133A (pt)
WO (1) WO2018079693A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201217A (zh) 2017-07-31 2020-05-26 斯玛尔药物有限公司 羟基去甲氯胺酮的晶型
GB201808150D0 (en) * 2018-05-18 2018-07-11 Small Pharma Ltd Therapeutic compounds
EP3737665A4 (en) 2018-01-10 2021-11-03 XWPharma Ltd. PRODRUGS OF KETAMINE, COMPOSITIONS AND USES THEREOF
CN108863873A (zh) * 2018-06-26 2018-11-23 台州学院 一种硫烯丙基碳酸酯类化合物及其制备方法
EP3860579A1 (en) 2018-10-05 2021-08-11 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020237747A1 (zh) * 2019-05-24 2020-12-03 北京大学深圳研究生院 一种长效化合物在制备药物中的应用
CN110559282A (zh) * 2019-08-02 2019-12-13 华中科技大学同济医学院附属同济医院 去甲氯胺酮在制备抗抑郁的药物中的应用
TW202135782A (zh) * 2019-12-20 2021-10-01 昱展新藥生技股份有限公司 氯胺酮雙羥萘酸鹽的長效注射劑型
US20230303481A1 (en) * 2020-08-31 2023-09-28 Shenzhen Ruijian Biotechnology Co., Ltd Long-acting low-addiction hnk derivative and preparation method therefor
CN112521295B (zh) * 2020-08-31 2021-10-08 深圳瑞健生物科技有限公司 一种长效低成瘾性化合物及其制备方法
WO2022041172A1 (zh) * 2020-08-31 2022-03-03 深圳瑞健生物科技有限公司 一种长效低成瘾性化合物在制备药物中的应用
WO2022041175A1 (zh) * 2020-08-31 2022-03-03 深圳瑞健生物科技有限公司 一种长效低成瘾性hnk衍生物在制备药物中的应用
US11690811B2 (en) 2021-08-13 2023-07-04 XWPharma Ltd. Pharmaceutical compositions and oral dosage forms of ketamine derivatives
EP4289815A1 (en) 2022-06-10 2023-12-13 Pcas Crystalline forms of norketamine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
AU2003291037A1 (en) * 2002-11-18 2004-06-15 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
CN104395283A (zh) * 2011-10-14 2015-03-04 美国政府健康及人类服务部 (2r,6r)-羟基去甲氯胺酮、(s)-脱氢去甲氯胺酮以及(r,s)-氯胺酮的其他立体异构脱氢和羟基化代谢物在治疗忧郁症和神经性疼痛中的应用
US20130236573A1 (en) * 2012-03-12 2013-09-12 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
CA2923685C (en) 2013-09-13 2022-03-08 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
WO2015051259A1 (en) * 2013-10-04 2015-04-09 Impax Laboratories, Inc. Pharmaceutical compositions and methods of use
CA2961208A1 (en) * 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
CA2966737A1 (en) * 2014-11-04 2016-05-12 Amorsa Therapeutics, Inc. Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
JP6304121B2 (ja) 2015-05-13 2018-04-04 信越化学工業株式会社 紫外線吸収性有機ケイ素化合物、塗料、及び積層体

Also Published As

Publication number Publication date
EP3533444A1 (en) 2019-09-04
EP3533444A4 (en) 2020-05-20
IL266133A (en) 2019-06-30
CN110167541A (zh) 2019-08-23
AU2017351437B2 (en) 2022-01-27
JPWO2018079693A1 (ja) 2019-10-31
WO2018079693A9 (ja) 2018-07-26
US20190240184A1 (en) 2019-08-08
JP2022081648A (ja) 2022-05-31
CA3041275A1 (en) 2018-05-03
AU2017351437A1 (en) 2019-06-06
JP2024038066A (ja) 2024-03-19
WO2018079693A1 (ja) 2018-05-03

Similar Documents

Publication Publication Date Title
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112015019720B8 (pt) Inibidores de (benzil-ciano-metil)-amidas de ácido 2-azabiciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c e composição farmacêutica
NI201900098A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112017023904A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112018069601A2 (pt) derivados de indolina substituídos como inibidores da replicação viral da dengue
NI201900119A (es) Derivados de indolina sustitudos como inhibidores de la replicación vírica de dengue
BR112015027682A2 (pt) Uso de sobetirome no tratamento de doenças ou condições associadas com a desmielinização ou mielinização insuficiente
BR112019003932A2 (pt) composto, composição farmacêutica, combinação, método de tratamento de uma doença ou desordem e uso do composto
BR112012030029A2 (pt) beta-lactamases modificadas e métodos e usos relacionados a elas
BR112017003433A2 (pt) inibidores espirocíclicos de catepsina c
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112017015123A2 (pt) derivados de indol como inibidores da replicação viral do dengue
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]